Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

NCT06428500 is registered in ClinicalTrials.gov with Quanta Therapeutics as lead sponsor.

NCT NCT06428500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06428500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Lead sponsor
Quanta Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 30, 2024
Completion date
July 1, 2027
Enrollment
240 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor